Making a vaccine against the coronavirus is a complicated, months-long process. Pfizer is working to get it done faster. It still takes time.
Author: Elizabeth Weise and Karen Weintraub, USA TODAY
Where did COVID-19 come from?
As the U.S. marks one year since its first case, questions remain about the origin of the coronavirus that causes the disease. The answers matter.
Key committee endorses Pfizer’s COVID-19 vaccine, paving way for clearance by FDA and vaccinations in US to begin
The endorsement paves the way for a final decision by the FDA, and mass vaccinations to begin within days.
CDC-convened committee votes to add nursing home residents to first phase of COVID-19 vaccine access
Everyone in Phase 1a should be able to get the first of the two-shot COVID-19 vaccine series within three weeks of one being authorized by the FDA.
USA TODAY vaccine panel: ‘Best news so far’ in COVID-19 fight, but logistical challenges remain
Expert panel pushes USA TODAY’s COVID-19 vaccine clock ahead on positive news, but logistical challenges loom in getting doses to Americans.
Johnson & Johnson pauses COVID-19 vaccine trial due to unexplained illness — the second US trial now on hold
The Phase 3 clinical trial was temporarily halted Monday because of an unexplained illness in one of the participants, Johnson & Johnson said.
Trump is receiving lots of medical care. Some doctors wonder if it’s too much.
All treatments carry risks, and any one of the therapies Trump is taking might be harmful alone or in combination with other therapies, the doctors said.